Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort

Tracy A Williams, Jacques W M Lenders, Paolo Mulatero, Jacopo Burrello, Marietta Rottenkolber, Christian Adolf, Fumitoshi Satoh, Laurence Amar, Marcus Quinkler, Jaap Deinum, Felix Beuschlein, Kanako K Kitamoto, Uyen Pham, Ryo Morimoto, Hironobu Umakoshi, Aleksander Prejbisz, Tomaz Kočjan, Mitsuhide Naruse, Michael Stowasser, Tetsuo Nishikawa, William F Young Jr, Celso E Gomez-Sanchez, John W Funder, Martin Reincke, for the Primary Aldosteronism Surgery Outcome (PASO) investigators

Summary

Background Although unilateral primary aldosteronism is the most common surgically correctable cause of hypertension, no standard criteria exist to classify surgical outcomes. We aimed to create consensus criteria for clinical and biochemical outcomes and follow-up of adrenalectomy for unilateral primary aldosteronism and apply these criteria to an international cohort to analyse the frequency of remission and identify preoperative determinants of successful outcome.

Methods The Primary Aldosteronism Surgical Outcome (PASO) study was an international project to develop consensus criteria for outcomes and follow-up of adrenalectomy for unilateral primary aldosteronism. An international panel of 31 experts from 28 centres, including six endocrine surgeons, used the Delphi method to reach consensus. We then retrospectively analysed follow-up data from prospective cohorts for outcome assessment of patients diagnosed with unilateral primary aldosteronism by adrenal venous sampling who had undergone a total adrenalectomy, consecutively included from 12 referral centres in nine countries. On the basis of standardised criteria, we determined the proportions of patients achieving complete, partial, or absent clinical success and biochemical success in accordance with the consensus. We then used logistic regression analyses to identify preoperative factors associated with clinical and biochemical outcomes.

Findings Consensus was reached for criteria for six outcomes (complete, partial, and absent success of clinical and biochemical outcomes) based on blood pressure, use of antihypertensive drugs, plasma potassium and aldosterone concentrations, and plasma renin concentrations or activities. Consensus was also reached for two recommendations for the timing of follow-up assessment. For the international cohort analysis, we analysed clinical data from 705 patients recruited between 1994 and 2015, of whom 609 also had biochemical data. Complete clinical success was achieved in 259 (37%) of 705 patients, with a wide variance (range 17–62), and partial clinical success in an additional 334 (47%, range 35–60); complete biochemical success was seen in 656 (94%, 83–100) of 699 patients. Female patients had a higher likelihood of complete clinical success (odds ratio [OR] 2.25, 95% CI 1.40–3.62; p=0.001) and clinical benefit (complete plus partial clinical success; OR 2.89, 1.49–5.59; p=0.002) than male patients. Younger patients had a higher likelihood of complete clinical success (OR 0.95 per extra year, 0.92–0.98; p=0.004) and clinical benefit (OR 0.95 per extra year, 0.92–0.98; p=0.004). Higher levels of preoperative medication were associated with lower levels of complete clinical success (OR 0.80 per unit increase, 0.70–0.90; p<0.001).

Interpretation These standardised outcome criteria are relevant for the assessment of the success of surgical treatment in individual patients and will allow the comparison of outcome data in future studies. The variable baseline clinical characteristics of our international cohort contributed to wide variation in clinical outcomes. Most patients derive clinical benefit from adrenalectomy, with younger patients and female patients more likely to have a favourable surgical outcome. Screening for primary aldosteronism should nonetheless be done in every individual fulfilling US Endocrine Society guideline criteria because biochemical success without clinical success is by itself clinically important and older women and men can also derive post-operative clinical benefit.

Funding European Research Council; European Union’s Horizon 2020; Else Kröner-Fresenius Stiftung; Netherlands Organisation for Health Research and Development—Medical Sciences; Japanese Ministry of Health, Labour and Welfare; Ministry of Health, Slovenia; US National Institutes of Health; and CONICYT-FONDECYT (Chile).

Introduction Primary aldosteronism is a form of endocrine hypertension characterised by inappropriately high plasma aldosterone concentrations relative to suppressed plasma renin.1 The prevalence of primary aldosteronism is reported as 5% in the general hypertensive population, increasing to 10% in referred populations and 15–20% in patients with treatment-resistant hypertension,2 3 4
Evidence before this study

Adrenalectomy is the recommended treatment for unilateral primary aldosteronism in patients willing and able to undergo surgery. Proportions of patients with biochemical remission are high across various reports (96–100%); by contrast, clinical remission has been reported for a much wider range (20–72%) of patients. This variability might be real, across centres, or might reflect the absence of standardised criteria and differences in post-surgical follow-up. We noted 18 studies, published between 1998 and 2015, in which total adrenalectomy was used to treat unilateral primary aldosteronism; these studies used different outcome criteria that varied from normalisation of plasma potassium concentrations with normalisation or improvement of blood pressure to criteria that also took into account the use of antihypertensive drugs and plasma aldosterone and renin concentrations or plasma renin activities. These studies rarely separated biochemical criteria (plasma potassium, renin, and aldosterone measurements) from clinical criteria (blood pressure measurements and use of antihypertensive drugs).

The assessment of biochemical success of adrenalectomy separately from clinical success is important because a patient with primary aldosteronism can be correctly biochemically diagnosed and successfully treated, but maintain background primary hypertension after successful adrenalectomy.

Adrenalectomy is the recommended treatment for unilateral primary aldosteronism from different clinical expert centres to provide a basis for comparison of outcome data from different clinical centres.

Although estimates vary widely, several studies have shown a higher prevalence of cardiovascular and cerebrovascular morbidity and mortality in patients with primary hypertension matched for age, sex, and blood pressure, with resolution of excess risk after surgical or specific medical treatment. As such, early diagnosis and appropriate treatment of primary aldosteronism are essential to minimise the increased risk associated with this disorder.

Primary aldosteronism is classified into unilateral and bilateral forms of the disease, which must be distinguished because, although the unilateral form can respond well to adrenalectomy, the bilateral form is treated with mineralocorticoid receptor antagonists. Although adrenal venous sampling is the recommended procedure to distinguish primary aldosteronism subtypes, it is not widely available, with some centres relying on CT or MRI for determination of lateralisation.

Surgical treatment of unilateral primary aldosteronism should resolve the excessive aldosterone secretion in all patients. Persistence of primary aldosteronism after adrenalectomy suggests that the initial diagnosis was incorrect, with the patient having bilateral rather than unilateral primary aldosteronism. To define post-surgical outcomes, specific clinical and biochemical criteria are needed for persistent or recurrent disease. Reported proportions of patients achieving clinical remission vary widely between centres (16–72%); this variation is attributed to several underlying factors such as background primary hypertension, age, longstanding primary aldosteronism, advanced renal failure, or other comorbidities. However, heterogeneity might also reflect the absence of standardised criteria to classify outcomes of adrenalectomy for unilateral primary aldosteronism. As such, we hypothesised that standardised uniform outcome criteria applied across a large multicentre patient cohort might minimise the previously reported variation in outcome results. Such uniform criteria might not only improve clinical care of patients with primary aldosteronism, but could also provide a basis for comparison of outcome data from different clinical centres.

The objectives of the Primary Aldosteronism Surgical Outcome (PASO) study were to establish an international consensus for a set of standardised criteria for clinical and biochemical outcomes of adrenalectomy for unilateral primary aldosteronism; to apply these criteria to follow-up data in a large multicentre cohort of patients with primary aldosteronism from different clinical expert centres to calculate the proportion of patients achieving remission; to identify the preoperative determinants of successful outcome; and to determine the extent to which these outcome determinants might account for differing proportions of patients achieving complete success between centres.
دریافت فوری
متن کامل مقاله
امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات